Appln. No. 10/551,263 Amd. dated June 12, 2008

Reply to Office Action dated: December 12, 2007

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Original) A modified Staphylococcal enterotoxin
 B (SEB) having a reduced reactivity with a neutralizing antibody
 to SEB (anti-SEB antibody).
- 2. (Original) The modified SEB of claim 1 wherein the reactivity with the anti-SEB antibody was reduced by introducing arbitrary amino acid substitution in the amino acid sequence of SEB.
- 3. (Original) The modified SEB of claim 2 wherein the amino acid substitution was introduced at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.
- 4. (Previously presented) The modified SEB of claim 2 wherein the amino acid substitution was introduced within a region from Lys at 226-position to Lys at 229-position in the amino acid sequence of SEB.

Appln. No. 10/551,263 Amd. dated June 12, 2008

Reply to Office Action dated: December 12, 2007

- 5. (Original) The modified SEB of claim 4 wherein the amino acid sequence of from 226-position to 229-position in the amino acid sequence of SEB is Leu Phe Ala Ala.
- 6. (Original) The modified SEB of claim 4 wherein the amino acid sequence of from 226-position to 229-position in the amino acid sequence of SEB is Ala Thr Thr Gln.
- 7. (Original) The modified SEB of claim 4 wherein the amino acid sequence of from 226-position to 229-position in the amino acid sequence of SEB is Lys Arg Ile Ile.
- 8. (Previously presented) The modified SEB of claim
 1 wherein Asn at 23-position in the amino acid sequence of SEB
 is substituted with Tyr.
- 9. (Currently Amended) A prophylactic/remedy adapted for immunopathy comprising

as an active ingredient the modified SEB as set forth in claim 1,

wherein said prophylactic/remedy <u>has provides</u> a reduced immunological response to SEB and an inhibitory activity to T cell activation,

Appln. No. 10/551,263 Amd. dated June 12, 2008 Reply to Office Action dated: December 12, 2007

said prophylactic/remedy being in a form adapted for immunopathy.

- 10. (Original) The prophylactic/remedy for immunopathy of claim 9 wherein said immunopathy is rheumatoid arthritis.
- 11. (Currently Amended) The prophylactic/remedy for immunopathy of claim 9 which is in a wherein said form is a form for oral administration.
- 12. (Previously presented) The modified SEB of claim 2 wherein Asn at 23-position in the amino acid sequence of SEB is substituted with Tyr.
- 13. (Previously presented) The modified SEB of claim 3 wherein Asn at 23-position in the amino acid sequence of SEB is substituted with Tyr.
- 14. (Previously presented) The modified SEB of claim 4 wherein Asn at 23-position in the amino acid sequence of SEB is substituted with Tyr.

Appln. No. 10/551,263 Amd. dated June 12, 2008

Reply to Office Action dated: December 12, 2007

- 15. (Previously presented) The modified SEB of claim 5 wherein Asn at 23-position in the amino acid sequence of SEB is substituted with Tyr.
- 16. (Previously presented) The modified SEB of claim 6 wherein Asn at 23-position in the amino acid sequence of SEB is substituted with Tyr.
- 17. (Previously presented) The modified SEB of claim
 7 wherein Asn at 23-position in the amino acid sequence of SEB
 is substituted with Tyr.
- a form adapted for immunopathy comprising as an active ingredient the modified SEB as set forth in claim 8, wherein said prophylactic/remedy has provides a reduced immunological response to SEB and an inhibitory activity to T cell activation.
- 19. (Currently amended) The prophylactic/remedy for immunopathy of claim 18 which wherein said form is [[in]] a form for oral administration.

Appln. No. 10/551,263 Amd. dated June 12, 2008 Reply to Office Action dated: December 12, 2007

- 20. (Previously presented) The prophylactic/remedy for immunopathy of claim 18 wherein said immunopathy is rheumatoid arthritis.
- 21. (New) A modified Staphylococcal enterotoxin

 B (SEB) having a reduced reactivity with a neutralizing antibody
 to SEB (anti-SEB antibody),

capable of being expressed in a soluble form in E.

coli to be maintained stably in an aqueous solution and that retains a therapeutic effect to immunopathy equivalent to that of naturally occurring SEB,

wherein the reactivity with anti-SEB antibody is reduced by introducing in the amino acid sequence of SEB an amino acid substitution from Lys at the 226-position to Lys at the 229-position of Leu Phe Ala Ala, Ala Thr Thr Gln or Lys Arg Ile Ile.